摘要
近年来,随着乳腺癌发病机制的研究逐渐深入、免疫组化分型更加精确,内分泌治疗逐渐成为针对乳腺癌进行明确靶点治疗且确认有效的治疗方法。在乳腺癌内分泌治疗的药物选择中,他莫昔芬(TAM)与托瑞米芬(TOR)先后被美国食品和药物管理局批准用于围绝经期激素受体阳性的乳腺癌。国内外多项研究对TOR与TAM分别单独或者联合应用于乳腺癌内分泌治疗进行了比较,但研究结果不尽一致。本文将围绕TOR与TAM在乳腺癌内分泌治疗中的有效性、安全性、生存质量以及经济效益,探讨TOR与TAM在乳腺癌内分泌治疗的临床进展。
In recent years, with the gradually deeper research on the pathogenesis of breast cancer, and more accurate immunohistochemical classification, the endocrine therapy has become a clear target treatment with confirmed e？cacy for breast cancer. In the drug selection of endocrine therapy for breast cancer, tamoxifen and toremifene has been approved by the US Food and Drug Administration （FDA） successively for breast cancer in positive hormone receptor of peri-menopausal period. A number of domestic and foreign researches have been done comparing using toremifene or tamoxifen alone, or the combination of the two drugs in the endocrine therapy for breast cancer. However, the research results are not consistent. This article will focus on the efficacy, safety, quality of life and economic benefits in the endocrine therapy of breast cancer by using toremifene and tamoxifen, and to discuss the clinical progress of toremifene and tamoxifen in endocrine therapy for breast cancer.
出处
《中华普通外科学文献（电子版）》
2017年第3期204-207,共4页
Chinese Archives of General Surgery(Electronic Edition)
作者简介
通信作者：任予，Email：renyyyyy@126．com
